Value investors often look for stocks that appear cheap, but a low valuation alone is rarely enough. A more disciplined approach combines valuation with fundamental quality, which is exactly what a Decent Value screen is designed to do. One stock that currently emerges from that methodology is PROGYNY INC (NASDAQ:PGNY), a fertility benefits management company that pairs a reasonable valuation with strong scores on profitability, health, and growth.
The Decent Value approach
This screen does not simply hunt for the lowest price-to-earnings ratio. Instead, it selects companies with an attractive ChartMill Valuation rating while requiring the underlying business to hold up on other fundamental dimensions. By demanding solid marks for profitability, health, and growth, the methodology aims to separate genuine bargains from value traps. That distinction matters because a cheap stock can remain cheap if the business is deteriorating behind the numbers.
What the screen sees in Progyny
For Progyny, the ChartMill fundamental report assigns an overall rating of 7 out of 10. Health is the standout score at 9, profitability comes in at 8, and both valuation and growth register at 7. In other words, this is not a company that is statistically inexpensive but fundamentally weak. The balance sheet, earnings quality, and growth trajectory all support the valuation argument.
Key fundamental checkpoints
- Valuation: The forward price-to-earnings ratio is 16.88, below the S&P 500 forward multiple of 21.75. Progyny’s price-to-free-cash-flow ratio is cheaper than 85% of its industry peers, and its EV/EBITDA multiple is cheaper than 68% of the sector. The PEG ratio also looks favorable given expected EPS growth of 36.34% per year.
- Profitability: Return on invested capital is 15.68%, which beats 93% of peers. Return on equity is 17.35%, and return on assets is 10.98%. Operating margin sits at 8.99%, better than 73% of the industry.
- Health: Progyny carries no outstanding debt, leaving debt-to-equity and debt-to-free-cash-flow ratios at zero. The Altman-Z score of 7.90 is among the best in the industry, while the current ratio of 2.14 signals solid short-term liquidity.
- Growth: EPS grew 55.93% over the past year and has compounded at roughly 52.04% annually in recent years. Revenue has grown at an average annual rate of 30.16%, and forecasts still point to EPS growth of 28.24% per year going forward.
Investors who want to check the underlying metrics and scorecards in more detail can open the full fundamental analysis report.
The value case, with caveats
The combination of a reasonable entry valuation and high health and profitability scores makes Progyny a relevant candidate for value investors who want more than just a low multiple. A debt-free balance sheet adds a margin of safety, while the expected earnings growth helps justify the forward price. Still, there are limitations to keep in mind. Progyny does not pay a dividend, so income-focused value investors may look elsewhere. Its profit margin has declined recently, and revenue growth is projected to moderate from the historical pace. A screen can identify candidates, but it does not remove the need for ongoing monitoring.
Another screen adds cash-flow confirmation
A separate screen focused on high free cash flow stocks also flags Progyny, noting that it generates strong free cash flow relative to its market price. That reinforces the main thesis: the valuation is backed by real cash generation, not just earnings quality.
More value candidates
The same methodology that surfaced Progyny can be used to scan for similar opportunities across the broader market. Investors who want to apply this quality-aware, value-oriented approach to a larger universe can find additional candidates on the Decent Value screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Progyny (NASDAQ:PGNY): A Decent Value Stock Combining Reasonable Valuation and Solid Fundamentals
Value investors often look for stocks that appear cheap, but a low valuation alone is rarely enough. A more disciplined approach combines valuation with fundamental quality, which is exactly what a Decent Value screen is designed to do. One stock that currently emerges from that methodology is PROGYNY INC (NASDAQ:PGNY), a fertility benefits management company that pairs a reasonable valuation with strong scores on profitability, health, and growth.
The Decent Value approach
This screen does not simply hunt for the lowest price-to-earnings ratio. Instead, it selects companies with an attractive ChartMill Valuation rating while requiring the underlying business to hold up on other fundamental dimensions. By demanding solid marks for profitability, health, and growth, the methodology aims to separate genuine bargains from value traps. That distinction matters because a cheap stock can remain cheap if the business is deteriorating behind the numbers.
What the screen sees in Progyny
For Progyny, the ChartMill fundamental report assigns an overall rating of 7 out of 10. Health is the standout score at 9, profitability comes in at 8, and both valuation and growth register at 7. In other words, this is not a company that is statistically inexpensive but fundamentally weak. The balance sheet, earnings quality, and growth trajectory all support the valuation argument.
Key fundamental checkpoints
Investors who want to check the underlying metrics and scorecards in more detail can open the full fundamental analysis report.
The value case, with caveats
The combination of a reasonable entry valuation and high health and profitability scores makes Progyny a relevant candidate for value investors who want more than just a low multiple. A debt-free balance sheet adds a margin of safety, while the expected earnings growth helps justify the forward price. Still, there are limitations to keep in mind. Progyny does not pay a dividend, so income-focused value investors may look elsewhere. Its profit margin has declined recently, and revenue growth is projected to moderate from the historical pace. A screen can identify candidates, but it does not remove the need for ongoing monitoring.
Another screen adds cash-flow confirmation
A separate screen focused on high free cash flow stocks also flags Progyny, noting that it generates strong free cash flow relative to its market price. That reinforces the main thesis: the valuation is backed by real cash generation, not just earnings quality.
More value candidates
The same methodology that surfaced Progyny can be used to scan for similar opportunities across the broader market. Investors who want to apply this quality-aware, value-oriented approach to a larger universe can find additional candidates on the Decent Value screen.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »